Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label study of NS-32 (ferric derisomaltose) for iron deficiency anemia associated with postpartum hemorrhage
jRCT2080224805Phase 3Completed
- Sponsor
- Nippon Shinyaku
- Start
- Jul 2019
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ferric derisomaltose in iron deficiency anemia (IDA) and anaemia, sponsored by Nippon Shinyaku. Primary endpoint: Maximum change in hemoglobin from baseline. Started Jul 2019; status: completed.
02
Drugs
ferric derisomaltose
03
Conditions
iron deficiency anemia (IDA)anaemia
Beyond the preview
Go deeper on jRCT2080224805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224805.